Analysis of five active ingredients of Er‐Zhi‐Wan, a traditional Chinese medicine water‐honeyed pill, using the biopharmaceutics classification system

2019 ◽  
Vol 34 (2) ◽  
Author(s):  
Xuexiao Cao ◽  
Huanhuan Li ◽  
Meng Wang ◽  
Xiaoliang Ren ◽  
Yanru Deng
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Classification System ◽  
Biopharmaceutics Classification System ◽  
Active Ingredients ◽  
Biopharmaceutics Classification

scholarly journals ICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9): Toward Harmonization in Latin American Countries

Pharmaceutics ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 363
Author(s):  
Claudia Miranda ◽  
Alexis Aceituno ◽  
Mirna Fernández ◽  
Gustavo Mendes ◽  
Yanina Rodríguez ◽  
...  
Keyword(s):  
Latin American ◽  
Classification System ◽  
Biopharmaceutics Classification System ◽  
In Vitro Dissolution ◽  
Ich Guidelines ◽  
Latin American Region ◽  
Regulatory Guidelines ◽  
Biopharmaceutics Classification

The biopharmaceutical classification system (BCS) is a very important tool to replace the traditional in vivo bioequivalence studies with in vitro dissolution assays during multisource product development. This paper compares the most recent harmonized guideline for biowaivers based on the biopharmaceutics classification system and the BCS regulatory guidelines in Latin America and analyzes the current BCS regulatory requirements and the perspective of the harmonization in the region to develop safe and effective multisource products. Differences and similarities between the official and publicly available BCS guidelines of several Latin American regulatory authorities and the new ICH harmonization guideline were identified and compared. Only Chile, Brazil, Colombia, and Argentina have a more comprehensive BCS guideline, which includes solubility, permeability, and dissolution requirements. Although their regulatory documents have many similarities with the ICH guidelines, there are still major differences in their interpretation and application. This situation is an obstacle to the successful development of safe and effective multisource products in the Latin American region, not only to improve their access to patients at a reasonable cost, but also to develop BCS biowaiver studies that fulfill the quality standards of regulators in developed and emerging markets.

scholarly journals COMPARISON OF GLOBAL REGULATORY GUIDELINES FOR AVAILABILITY OF DIFFERENT BIOWAIVER PROVISIONS AND APPLICATION REQUIREMENTS OF BIOPHARMACEUTICS CLASSIFICATION SYSTEM (BCS) BASED BIOWAIVER.

2018 ◽  
Vol 3 (3) ◽  
pp. 8-20
Author(s):  
Jimi Patel ◽  
Priti Mehta ◽  
Vaishali Kothari
Keyword(s):  
Development Strategy ◽  
Classification System ◽  
Drug Application ◽  
Biopharmaceutics Classification System ◽  
New Drug ◽  
Novel Approach ◽  
Permeability Study ◽  
New Drug Application ◽  
Biopharmaceutics Classification

To waive a complete and systemic Bioequivalence (BE) study, Biowaiver or Request for a Biowaiver is a fast track approach to boost the drug development process. Over the past three-four years the Biowaiver market shows greater number of Biowaiver submissions and the wider use of In-vitro permeability study. Biowaiver is a beneficial approach for getting approval of Abbreviated New Drug Application (ANDA) while, BCS based Biowaiver is the novel approach to gain approval for New Drug Application (NDA) as well as ANDA. A Biopharmaceutics Classification System (BCS) based Biowaiver is an exemption from conducting human bioequivalence studies when active ingredient and dosage form meet criteria of solubility, permeability and dissolution. The Paper covers different kind of Biowaiver approaches and the criteria for the applicability of BCS based Biowaivers in the different geographic scopes with regard to global development strategy. There is a comparison of global guidelines on provisions availability for different types of Biowaiver approaches as well as for requirements of Biowaiver based on BCS. From comparison of different global guidelines it is reviewed that most of the guidance resembles to the USFDA, EU and WHO guidelines because most of the regulatory authorities are following the BCS based Biowaiver concept as one of the three main guidance documents (USFDA, EMA, WHO) or a combination of specific requirements.

scholarly journals Stability of Active Ingredients of Traditional Chinese Medicine (TCM)

2009 ◽  
Vol 4 (12) ◽  
pp. 1934578X0900401 ◽  
Author(s):  
Wang Meng ◽  
Ren Xiaoliang ◽  
Gao Xiumei ◽  
Franco Francesco Vincieri ◽  
Anna Rita Bilia
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Animal Origin ◽  
Active Ingredients ◽  
Rational Development ◽  
Plant Constituents ◽  
Crude Drugs ◽  
The Stability ◽  
First Time

Studies on stability of active ingredients are fundamental and critical for the rational development of Traditional Chinese Medicine (TCM) in view of its modernization and worldwide use. The stability of both active and marker constituents of plants used in TCM is reviewed for the first time. More than 100 papers, mostly written in Chinese, have been reviewed. Studies concerning plant constituents were analyzed according to their chemical classification of active ingredients. In addition, several crude drugs of animal origin are also reported. Stability of active ingredients is summarized during extraction and/or storage of the herbal drug preparations, and under stress conditions (pH, temperature, solvents, light, and humidity) and in the presence of preservatives, antioxidants, and metals.

Sign in / Sign up

Export Citation Format

Share Document